Top

Published in:

01-09-2004 | Brief Report

Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution

Authors: Angel Alonso Melgar, Marta Melgosa Hijosa, Rafael Pardo de la Vega, Carmen García Meseguer, Mercedes Navarro Torres

Published in: Pediatric Nephrology | Issue 9/2004

Abstract

Pure red cell aplasia is a rare complication of recombinant human erythropoietin (rHuEPO) treatment, which physicians should consider once the more frequent causes of hyporegenerative anemia have been excluded. To our knowledge, no pediatric cases have been described. In our patient, cyclosporin A treatment enabled a reduction in the number of transfusions and the risk of hyperimmunization. After transplantation, our patient’s hemoglobin level has remained normal and stable.

Bergrem H, Danielson BG, Eckardt K-U, Kurtz A, Stridsberg M (1993) A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Erythropoietin: molecular physiology and clinical application. Dekker, New York, pp 266–275

Peces R, Torre M de la, Alcázar R, Urra JM (1996) Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335:523–524CrossRefPubMed

Prabhakar SS, Muhlfelder T (1997) Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 47:331–335PubMed

Eckardt A-U, Casadevall N (2003) Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 18:865–869CrossRefPubMed

Bunn HF (2002) Drug-induced autoimmune red-cell aplasia. N Engl J Med 346:522–523PubMed

Krantz SB (1974) Pure red-cell aplasia. N Engl J Med 291:345–350PubMed

Kiely PDW, McGuckin CP, Collins DA, Bevan DH, Marsh JC (1995) Erythrocyte aplasia and systemic lupus erythematosus. Lupus 14:407–411

Agencia Española del Medicamento (2002) Comunicación sobre riesgos de medicamentos para profesionales sanitarios: Epoetina Alfa

Weber G, Gross J, Kromminga A, Loew HH, Eckardt K-U (2002) Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 13:2381–2383PubMed

10.

Cases A, Esforzado N, Mas M, Ricart MJ, Cruzado JM (2003) Aplasia pura de la serie roja asociada a anticuerpos neutralizantes frente a eritropoyetina inducida por epoetina alfa: una nueva forma de eritroblastopenia adquirida en pacientes urémicos. Nefrologia 23:266–270PubMed

11.

Chng W, Tan L, Liu T (2003) Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis 41:692–695CrossRefPubMed

12.

Duarte-Salazar C, Cazarin-Barrientos J, Goycoechea-Robles MV, Collazo-Jaloma J, Burgos-Vargas R (2000) Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with cyclosporin A. Rheumatology 39:1155–1157CrossRef

Title: Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution
Authors: Angel Alonso Melgar
Marta Melgosa Hijosa
Rafael Pardo de la Vega
Carmen García Meseguer
Mercedes Navarro Torres
Publication date: 01-09-2004
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 9/2004
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-004-1489-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2004

To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription

Poster Presentations P143 - 307

Influence of diet on atherogenic risk in children with renal transplants

Symposia Lectures

Single-dose daily administration of cyclosporin A for relapsing nephrotic syndrome

Risk factors for catheter-related complications in pediatric peritoneal dialysis